| Followers | 35 |
| Posts | 2798 |
| Boards Moderated | 0 |
| Alias Born | 10/28/2013 |
Friday, May 23, 2014 9:21:56 AM
I looked around the internet some months ago for articles on the effects of Temador on the immune system. I came across the article below that claims that at least in "many cases" there is substantial damage to the immune system from Temador during SOC for GBM with progression apparently occurring because the immune system has been so damaged.
It would have made sense for Merck to have settled on a GBM Temador regimen where there is typically a balance between the damage the Temador does to the Tumor, and the damage it does to the patient. At least, that makes sense to me. Actually the right thing to do. But if so, I don't think that the same Temador regimen would allow that balance when you add an adjunct, such as DCVax-L, or even Avastin. Not transparent to me, but using my foggy-logic radar, I'm pretty sure that the optimum amount of Temador in that case would be somewhat less.
Whether the damage that Temador does to the immune system is permanent or not, apparently in many cases, it is enough to allow progression, and death. At least according to the article below.
The moral that I get out of this is that however well DCVax-L is working, it might work even better with the simple change of reducing the number of cycles of Temador. You would think that the methylated patients could afford to role that back even a little further than the rest. Ie, that the optimum Temador regimen for them would be a little less still.
(Temador Immunosuppression Problems)
http://www.ncbi.nlm.nih.gov/pubmed/21737504
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
